Figure 1. Morphology of Activated Human T Cells Stimulated with ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator

A clustered morphology is seen in activated human T cells. Cells were isolated using EasySep™ Human T Cell Isolation Kit, stimulated with ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator for 3 days in ImmunoCult™-XF supplemented with recombinant human interleukin-2 (rhIL-2).

Figure 2. Activation of Human T Cells Stimulated with ImmunoCult™ Human CD3/CD28/CD2 Activator.

Human T cells were stimulated with ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator and cultured in ImmunoCult™-XF. Activation of viable CD4+ and CD8+ T cells were assessed by CD25 expression, using flow cytometry. Following 3 days of culture, the frequency of CD25-positive cells was (A) 91.4% for CD4+ T cells and (B) 87.8% for CD8+ T cells. The gray line depicts day 3 CD4+ and CD8+ T cells cultured without ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator.

Figure 3. Robust Human T Cell Expansion and High Viability Achieved Using ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator

Human T cells were expanded over 12 days with ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator in ImmunoCult™-XF supplemented with rhIL-2. On day 0, 1 x 10^6 isolated human T cells were stimulated with 25 μL of ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator in ImmunoCult™-XF supplemented with rhIL-2.No additional ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator was added during the 12-day culture period (mean ± SD in 3 experiments with 7 donors).